OncoTracking™ for Providers
Detect Early.
Treat with Confidence
The presence of higher levels of ctDNA is an immediate indication that malignant cancer may exist in the body. The presence of specific biomarkers helps immediately diagnose the type of disease. Reducing morbidity and mortality can be done by early detection of cancer, leading to treatment such as surgery before the tumor metastasizes.

  • 1
    Early Detection
    Detects cancer earlier than visual diagnostics (CT scan/MRI)
  • 2
    Customized assay
    Customized assay to detect your patient's specific type of cancer
  • 3
    Guide
    Provides list of relevant therapies and clinical trials for your patient's cancer

Diagnosis and Beyond
ctDNA provides real-time information regarding tumors in the body. In fact, treatment-resistance mutation can also be predicted in assays, indicating the need to use different drugs or therapies. For example, KRAS codon 61 is a mutation that has been observed to be associated with acquired resistance; when this is found in ctDNA, it implies cancer cannot be treated with anti-EGFT antibodies
OncoTracking™ Specimen Requirements
For tumor analysis
Send in tissue block (FFPE) containing tumor tissue. If a tissue block is not available, send 20 blank slides (8 um cut from the tumor tissue block). Include completed requisition.
For liquid biopsy analysis
10 Ml of blood in EDTA (purple top) tube. Include completed requisition.
When Should You Recommend OncoTracking™?
OncoTracking™ can be used to detect recurrence in patients who have successfully completed treatment. Traditional testing methods do not detect recurrence until the cancer has crown to a size that is detectable by imagining scan. Liquid biopsy allows us to detect cancer months earlier than such methods, allowing your patient to have less invasive treatments, minimal therapies and less anxiety about recurrence.
Join the Journey